UBS upgraded Ameren to Buy from Neutral with a price target of $87, up from $81, after resuming coverage of the name. The uncertainty created by the challenging regulatory outcome in Illinois last December has driven material underperformance in the stock, which now trades at 5% discount on estimated 2026 earnings, the analyst tells investors in a research note. The firm sees the “large headwind” from Illinois regulation as being more than priced in to the stock and believes this is an attractive entry point with upcoming catalysts.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AEE:
- Ameren price target lowered to $80 from $81 at BMO Capital
- Ameren Missouri doubles renewable energy program
- Ameren granted approval for acquisition of 150 MW solar facility in Missouri
- Ameren upgraded to Overweight on Illinois data points at Barclays
- Ameren upgraded to Overweight from Equal Weight at Barclays